262 related articles for article (PubMed ID: 31834023)
1. Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer.
Akbor M; Hung KF; Yang YP; Chou SJ; Tsai PH; Chien CS; Lin LT
J Chin Med Assoc; 2020 Feb; 83(2):113-116. PubMed ID: 31834023
[TBL] [Abstract][Full Text] [Related]
2. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
3. The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review.
Forner D; Horwich P; Trites JR; Hollenhorst H; Bullock M; Lamond NWD
Curr Oncol; 2020 Dec; 27(6):330-335. PubMed ID: 33380865
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
5. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
6. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
7. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
8. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract][Full Text] [Related]
9. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
10. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
11. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells.
Wimmer S; Deloch L; Hader M; Derer A; Grottker F; Weissmann T; Hecht M; Gostian AO; Fietkau R; Frey B; Gaipl US
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502022
[TBL] [Abstract][Full Text] [Related]
13. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
15. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
16. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
[TBL] [Abstract][Full Text] [Related]
20. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
